The International Regulome Consortium has announced its decision to tie up with the Invitrogen Corporation to facilitate stem cell research. The agreement was signed here yesterday at the annual meeting of the Biotechnology Industry Organization. Invitrogen will contribute services and technology to help IRC researchers to find out the use of stem cell in fatal diseases.

Dr. Michael Rudnicki, Scientific Director of the International Regulome Consortium and Senior Scientist at the Ottawa Health Research Institute in Ontario, Canada said, “I am delighted that Invitrogen has chosen to partner with the IRC. Invitrogen brings tremendous expertise and strength in stem cell biology to this important international consortium. Without question, this participation will accelerate the IRC’s research program.”

It is worthwhile to add that International Regulome Consortium (IRC) is a third generation genomics project mapping the genetic circuit board that regulates the formation and function of cells. The project will define the genetic regulation of different types of cells with an initial emphasis on those involved in the formation and function of neural tissues. IRC is using sophisticated laboratory techniques combined with advanced data analysis to determine how these genes are regulated in stem cells and in the specialized cells they give rise to. The new knowledge generated by IRC will set the stage for a powerful new paradigm of health-medicine centered on the regeneration of diseased or dysfunctional tissues that is at once personalized, predictive and preventive. For more information, see http://www.internationalregulomeconsortium.ca/.

Source: Cnnmoney.com